Thebiostartups Domain Overview🔒 SSL Verified

Table of Contents

• ↓ Success Stories
• ↓ Startups Spotlight
• ↓ Read BioStartups newsletter
• ↓ Ecosystem partners
• ↓ Bio-informatics
• ↓ BioStartups for you
• ↓ Top Alternatives to thebiostartups.com

6-Month Traffic Trend Estimate

Official Contact & Profiles

Visual representation extracted from thebiostartups.com

Content Snippets from thebiostartups.com

"Litemed India, a Hyderabad-based health-tech startup, has introduced Curapod M, a science-led solution developed specifically for menstrual pain and cramps. Fully engineered and manufactured in India, Curapod M brings together medical-grade photobiomodulation (PBM), adaptive personalisation and digital intelligence to address an experience that women have been expected to plan their lives around for generations. Curapod M is licensed by CDSCO and registered with the US FDA. At the centre of Curapod M is a clinically validated photobiomodulation platform designed to work on biological processes associated with menstrual pain, including prostaglandin-linked pathways involved in cramping. In clinical evaluation, 80% of women experienced zero pain after using Curapod M. Curapod M uses specific red and near-infrared wavelengths through photobiomodulation, supported by a proprietary adaptive engine that personalises therapy. Its companion app learns from the user’s cycle, pain patterns, and therapy history and is designed to anticipate the likely intensity of an upcoming cycle. Together, the device and app shift the experience from reacting to pain to anticipating and managing it more intelligently. Curapod M is expected to roll out across India through Curapod’s website, Amazon, and Flipkart, with an indicative launch price of around Rs 11,999. Availability will extend across metros and Tier 2 markets."

"TRUE ARTIS, an integrated aesthetic surgery platform, has raised Rs 11.4 crore in a seed round led by Zeropearl VC, with participation from Eleven, a diversified business group of Sunil Sachdeva, co-founder of Medanta, and a group of angel investors. The round also saw participation from operators and healthcare investors including Arjun Vaidya (V3 Ventures), Dr Dhruv Joshi (Co-founder, Cloud Physician), Ambarish Gupta (Founder & CEO, Basis Vectors Capital) and Vivek Lohcheb (CBO, PhonePe), along with former senior executives from Airtel and OYO. TRUE ARTIS will use the capital to open two new centres in Delhi NCR over the next six to eight months, deepen its surgical and recovery capabilities, expand its network of plastic and aesthetic surgeons, and strengthen its technology and patient-care systems. The company plans to consolidate its presence in Delhi NCR before expanding into other markets. The company operates its own purpose-built aesthetic surgery centres, where surgeries are performed on-site. The centres feature advanced operating theatres and surgical and medical equipment, dedicated recovery facilities, ICU backup and private patient suites. Designed specifically for aesthetic surgery, the centres are equipped to undertake complex procedures while providing patients greater privacy than a conventional multispecialty hospital setting. TRUE ARTIS also works with a multidisciplinary network of full-time and visiting plastic surgeons, giving patients access to different specialists under one platform rather than building the model around a single practitioner."

Key Topics & Focus Areas for thebiostartups.com:

Success Stories

Startups Spotlight

Read BioStartups newsletter

Ecosystem partners

Bio-informatics

BioStartups for you